AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Brea
AMSTERDAM, Netherlands—Some patients with breast cancer could soon be treated with surgery and targeted drugs without the need for chemotherapy—according to findings reported at the 2016 European Breast Cancer Conference by Judith Bliss, Professor of Clinical Trials at the Institute of Cancer Research, in Sutton, near London UK.
Patients whose cancers tested positive for the HER2 molecule responded in matter of days to a combination of the two drugs lapatinib plus trastuzumab used in the brief window between diagnosis and surgery in the UK EPHOS B study—indicating that such anti-HER2 drug combinations could be effective in the months following surgery—avoiding cytotoxic side effects such as hair loss and increased risk of heart disease.
SOURCE:
http://www.ecco-org.eu/Events/EBCC10/…
Abstract 6LB:
“Effects of perioperative lapatinib and trastuzumab, alone and in combination, in early HER2+ breast cancer – the UK EPHOS-B trial (CRUK/08/002)”
AJO Cancer Spotlight: Posted April 5th, 2016 By the Audio Journal of Oncology
Related Episodes
Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer
Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.
Jelle Wesseling MD PhD; 2026 EBCC: ‘Lord’ Trial Finds Active Surveillance for Estrogen-Receptor-Positive, HER2- Negative, Grade 1–2 DCIS Just As Effective as Standard Therapy
At the 2026 EBCC, Jelle Wesseling MD PhD discusses the LORD-trial, which found active surveillance for low-risk, estrogen-receptor-positive, HER2-negative, grade 1–2 DCIS is as effective as standard therapy. The trial's reassuring findings led to early cessation of randomization, supporting de-escal
Elisa Agostinetto MD; 2026 EBCC: Circulating Tumor DNA Trumps Clinical Prognostic Markers After Neoadjuvant Therapy for Patients with Early Breast Cancer
Elisa Agostinetto MD presented at EBCC 2026, highlighting circulating tumor DNA (ctDNA) as a superior prognostic marker over clinical indicators for predicting relapse and progression in early breast cancer patients after neoadjuvant therapy. This research supports ctDNA for post-neoadjuvant risk st